Dice Molecules Holdings Top Management

DICEDelisted Stock  USD 47.55  0.00  0.00%   
Dice Molecules employs about 71 people. The company is managed by 7 executives with a total tenure of roughly 166 years, averaging almost 23.0 years of service per executive, having 10.14 employees per reported executive. Evaluation of Dice Molecules' management performance can provide insight into the firm performance.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Dice Molecules Management Team Effectiveness

The company has return on total asset (ROA) of (0.1402) % which means that it has lost $0.1402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.216) %, meaning that it created substantial loss on money invested by shareholders. Dice Molecules' management efficiency ratios could be used to measure how well Dice Molecules manages its routine affairs as well as how well it operates its assets and liabilities.

Dice Molecules Workforce Comparison

Dice Molecules Holdings is one of the top stocks in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 157,114. Dice Molecules adds roughly 71.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Dice Molecules Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dice Molecules insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dice Molecules' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dice Molecules insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Dice Molecules Notable Stakeholders

A Dice Molecules stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dice Molecules often face trade-offs trying to please all of them. Dice Molecules' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dice Molecules' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Dice Molecules Management Performance

The success or failure of an entity such as Dice Molecules Holdings often depends on how effective the management is. Dice Molecules management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dice management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dice management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Dice Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people.
The data published in Dice Molecules' official financial statements usually reflect Dice Molecules' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dice Molecules Holdings. For example, before you start analyzing numbers published by Dice accountants, it's critical to develop an understanding of what Dice Molecules' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Dice Molecules' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dice Molecules' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dice Molecules' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dice Molecules Holdings. Please utilize our Beneish M Score to check the likelihood of Dice Molecules' management manipulating its earnings.

Dice Molecules Workforce Analysis

Traditionally, organizations such as Dice Molecules use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dice Molecules within its industry.

Dice Molecules Manpower Efficiency

Return on Dice Molecules Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.2M
Net Loss Per Executive12M
Working Capital Per Employee7.9M
Working Capital Per Executive80.4M
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Dice Molecules Holdings information on this page should be used as a complementary analysis to other Dice Molecules' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Dice Stock

If you are still planning to invest in Dice Molecules Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dice Molecules' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges